<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04637152</url>
  </required_header>
  <id_info>
    <org_study_id>HGeralRobertoSantos</org_study_id>
    <nct_id>NCT04637152</nct_id>
  </id_info>
  <brief_title>Sacubitril/Valsartan in Resistant Hypertension</brief_title>
  <acronym>HEVA</acronym>
  <official_title>Anti-Hypertensive Effect of Sacubitril/Valsartan in Resistant Hypertension: Randomized Clinical Trial - The HEVA Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Geral Roberto Santos</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitário Professor Edgard Santos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Geral Roberto Santos</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims to evaluate the antihypertensive effect of sacubitril/valsartan in&#xD;
      patients with resistant hypertension compared to the use of recommended and optimized&#xD;
      antihypertensive therapy, through a randomized clinical trial, over 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Worldwide, millions of people are affected by the arterial hypertension system (SAH), so that&#xD;
      the presence of resistant hypertension (RH) significantly influences a high cardiovascular&#xD;
      morbidity and mortality compared to those with controlled SAH, thus corroborating the need&#xD;
      for the development of agents antihypertensive drugs with favorable efficacy and safety&#xD;
      profiles. It is known that they are currently using the combined therapy recommended for this&#xD;
      group of patients, among them, a significant portion of individuals with RH are unable to&#xD;
      achieve the goal of BP control (&gt;140/90 mmHg) even though in regular use, being subject to&#xD;
      the greatest risk of cardiovascular outcomes and morbidity and mortality. Approved by the FDA&#xD;
      for use in heart failure with reduced ejection fraction with beneficial effects on morbidity&#xD;
      and mortality, identified in previous studies, the sacubitril/valsartan molecule (LCZ696) or&#xD;
      Entresto® is a molecular complex composed of the sacubitril prodrug activated after ingestion&#xD;
      in sacubitrilate - neprilysin inhibitor - associated with valsartan, an angiotensin II type-1&#xD;
      (AT1) receptor antagonist, with vasodilating action, capable of reducing BP, sympathetic&#xD;
      tone, with antifibrotic and anti-hypertrophic effects, in addition to natriuresis and&#xD;
      diuresis. Considering the knowledge gap to the benefits to LCZ696 in the control of blood&#xD;
      pressure in resistant hypertension, the objective of the present study is to evaluate the&#xD;
      efficacy (reduction of ambulatory systolic and diastolic blood pressure) and safety (adverse&#xD;
      events, hospitalization and cardiovascular death) of the use of sacubitril/valsartan in&#xD;
      comparison to the antihypertensive therapy recommended and optimized by the current&#xD;
      guidelines, in patients diagnosed with RH, over12 weeks, through a randomized clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2020</start_date>
  <completion_date type="Anticipated">November 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 11, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>Single (Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in systolic blood pressure and diastolic blood pressure in the sitting position.</measure>
    <time_frame>12 weeks</time_frame>
    <description>The mean reduction in systolic blood pressure and diastolic blood pressure in the sitting position</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean reduction in ambulatory systolic blood pressure (maSBP) and ambulatory diastolic blood pressure</measure>
    <time_frame>12 weeks</time_frame>
    <description>The mean reduction in ambulatory systolic blood pressure (maSBP) and ambulatory diastolic blood pressure (maDBP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety outcomes</measure>
    <time_frame>12 weeks</time_frame>
    <description>Rate of hypotension, angioedema, uncontrolled blood pressure above 220x120, relevant hydroelectrolytic disorders, hospitalization, stroke and other cardiovascular events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Resistant Hypertension</condition>
  <condition>Blood Pressure</condition>
  <arm_group>
    <arm_group_label>Group A: Usual recommended therapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Antihypertensive regimen based on the usual recommended (optimized) therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Sacubitril/Valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suspension of ACE inhibitors - for at least 36h of the last dose - or ARB. Initial dosage: Sacubitril/valsartan 49mg/51mg, 1 tablet twice daily. Target dose (after two weeks): 97mg/103 mg, 1 tablet twice daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril-Valsartan</intervention_name>
    <description>Use of sacubitril/valsartan after suspension of ACE inhibitors or ARBs.</description>
    <arm_group_label>Group B: Sacubitril/Valsartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men or women, over 18;&#xD;
&#xD;
          -  Diagnosed with resistant hypertension (using three or more antihypertensive agents of&#xD;
             different classes - eg. angiotensin-converting enzyme inhibitor, angiotensin II&#xD;
             receptor blocker, calcium channel blockers, loop and thiazide diuretics or&#xD;
             potassium-sparing diuretics), at least 4 weeks before recruitment, with a BP that&#xD;
             remains above the goal of 140/90 mmHg.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary and treatable hypertension;&#xD;
&#xD;
          -  History of angioedema; significant cerebrovascular disease;&#xD;
&#xD;
          -  Active liver disease (alanine aminotransferase or aspartate aminotransferase &gt; 2 times&#xD;
             the upper limit of the normal range and)&#xD;
&#xD;
          -  Kidney dialysis or kidney transplantation or serum creatinine&gt; 1.5 times the upper&#xD;
             limit of the normal range or CrCl &lt;30 mL/min;&#xD;
&#xD;
          -  Previous or current diagnosis of heart failure;&#xD;
&#xD;
          -  Malignancy;&#xD;
&#xD;
          -  Any significant laboratory abnormalities such as serum potassium &gt; 5.5 mmol/L.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>General Hospital Roberto Santos</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40301-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andre R Duraes, M.D, PhD</last_name>
      <phone>71991888399</phone>
      <email>andreduraes@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Andre R Duraes, M.D, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitário Professor Edgard Santos</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>40301-155</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roque A Junior, M.D, PhD</last_name>
      <phone>71981767863</phone>
      <email>roque.aras@uol.com.br</email>
    </contact>
    <investigator>
      <last_name>Yasmin SL Bitar, B.S</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristiano Ricardo B de Macedo, M.D, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roque A Junior, M.D, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 14, 2020</study_first_submitted>
  <study_first_submitted_qc>November 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 27, 2020</last_update_submitted>
  <last_update_submitted_qc>November 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Geral Roberto Santos</investigator_affiliation>
    <investigator_full_name>Andre Rodrigues Duraes</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>Resistant Hypertension</keyword>
  <keyword>LCZ696</keyword>
  <keyword>Blood pressure control</keyword>
  <keyword>sacubitril/valsartan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

